NO20064200L - Fremgangsmate for syntese av en CXCR4-antagonist - Google Patents

Fremgangsmate for syntese av en CXCR4-antagonist

Info

Publication number
NO20064200L
NO20064200L NO20064200A NO20064200A NO20064200L NO 20064200 L NO20064200 L NO 20064200L NO 20064200 A NO20064200 A NO 20064200A NO 20064200 A NO20064200 A NO 20064200A NO 20064200 L NO20064200 L NO 20064200L
Authority
NO
Norway
Prior art keywords
protected
synthesis
amine
imine
reacting
Prior art date
Application number
NO20064200A
Other languages
English (en)
Inventor
Trevor R Wilson
Jason Crawford
Gang Chen
Ian Baird
Renato T Skjerlj
David Gauthier
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20064200L publication Critical patent/NO20064200L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåte for syntese av heterocykliske farmasøytiske forbindelser som bindes til CXCR4 chemokinreseptoren. I én utførelsesform, omfatter fremgangsmåten: a) omsetning av et 5,6,7,8-tetrahydrokinolinylamin og et alkylaldehyd som bærer en ftalimid eller en di-tertiær-butoksykarbonyl (di-BOC) beskyttelsesgruppe for å danne et imin; b) reduksjon av iminet for å danne et sekundært amin; c) omsetning av det sekundære aminet med en halogenalkyl substituert heterocyklisk forbindelse, for å danne et ftalimido-beskyttet eller di-tert-butoksykarbonyl beskyttet tertiær amin; og d) hydrolyse av det beskyttede aminet for å oppnå en forbindelse som har Formel I'
NO20064200A 2004-03-15 2006-09-15 Fremgangsmate for syntese av en CXCR4-antagonist NO20064200L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55358904P 2004-03-15 2004-03-15
PCT/US2005/008268 WO2005090308A1 (en) 2004-03-15 2005-03-11 Process for the synthesis of a cxcr4 antagonist

Publications (1)

Publication Number Publication Date
NO20064200L true NO20064200L (no) 2006-09-15

Family

ID=34993619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064200A NO20064200L (no) 2004-03-15 2006-09-15 Fremgangsmate for syntese av en CXCR4-antagonist

Country Status (13)

Country Link
US (1) US7332605B2 (no)
EP (1) EP1730113B1 (no)
JP (1) JP4870660B2 (no)
KR (1) KR20060131899A (no)
CN (1) CN1930127B (no)
AU (1) AU2005224079A1 (no)
BR (1) BRPI0508703B8 (no)
CA (1) CA2558389C (no)
ES (1) ES2614508T3 (no)
IL (1) IL177511A (no)
NO (1) NO20064200L (no)
RU (1) RU2006136381A (no)
WO (1) WO2005090308A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
PE20060646A1 (es) * 2004-08-16 2006-08-04 Smithkline Beecham Corp Derivados de bencimidazol como moduladores de la actividad de quimioquinas
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
WO2007087548A2 (en) * 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
JP2009545620A (ja) * 2006-08-02 2009-12-24 ジェンザイム・コーポレーション 併用療法
WO2008134326A1 (en) * 2007-04-26 2008-11-06 Dow Global Technologies Inc. Novel aldehyde composition
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
BR112022022243A2 (pt) 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
JP2024538727A (ja) * 2021-10-07 2024-10-23 エックス４ ファーマシューティカルズ， インコーポレイテッド マボリキサフォルの合成およびその中間体
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质
WO2024216075A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216095A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216114A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
IL133212A (en) * 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
RU2289581C2 (ru) * 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
CZ10903U1 (en) * 2001-01-11 2001-02-19 Oldrich Ing Cihak Bladed water wheel
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
CN1930127A (zh) 2007-03-14
IL177511A0 (en) 2006-12-10
KR20060131899A (ko) 2006-12-20
JP2007529526A (ja) 2007-10-25
ES2614508T3 (es) 2017-05-31
EP1730113A4 (en) 2009-12-02
EP1730113B1 (en) 2016-12-28
US7332605B2 (en) 2008-02-19
JP4870660B2 (ja) 2012-02-08
BRPI0508703A (pt) 2007-08-07
IL177511A (en) 2010-12-30
EP1730113A1 (en) 2006-12-13
CN1930127B (zh) 2012-11-21
US20050209277A1 (en) 2005-09-22
RU2006136381A (ru) 2008-04-27
BRPI0508703B8 (pt) 2021-05-25
WO2005090308A1 (en) 2005-09-29
BRPI0508703B1 (pt) 2020-11-24
CA2558389C (en) 2013-10-08
AU2005224079A1 (en) 2005-09-29
CA2558389A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
BRPI0508703B8 (pt) processo para a síntese de um antagonista de cxcr4
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
BRPI0519597A2 (pt) derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose
DK1776377T3 (da) Nyt steroid til FXR
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
MX2008014908A (es) Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
WO2008007113A3 (en) Pharmaceutical combinations
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
NO20073701L (no) Nye fremgangsmater for fremstilling av et 2H-kromen
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
BRPI0510335A (pt) composto heterocìclico
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application